scholarly journals VOLUME PLASMA DAN FAKTOR VIII DALAM KRIOPRESIPITAT

2016 ◽  
Vol 19 (1) ◽  
pp. 9
Author(s):  
Dian Widyaningrum ◽  
Purwanto AP ◽  
Julia Setyati
Keyword(s):  
Factor Viii ◽  
Blood Group ◽  
Von Willebrand Factor ◽  
Plasma Volume ◽  
Fresh Frozen Plasma ◽  
Factor Viii Level ◽  
Viii Level ◽  
Fresh Frozen ◽  
Von Willebrand ◽  
Willebrand Factor

Blood product such as cryoprecipitate required a quality control. This includes development, implementation and the standard operating procedures use of each step of the process in the production of cryoprecipitated substance to ensure that the produced product contains a minimum of 80 international units (IU) of factor VIII. Cryoprecipitation is prepared from fresh frozen plasma that thawed and centrifuge by immediate spinning the excess plasma which then removed and leaving approximately 40ml which deposit 10 mL cryoprecipitate. One unit of cryoprecipitate contain 70–80 IU/unit factor VIII, ≥100 mg/unit von Willebrand factor, fibrinogen 5–10 mg/dL. The levels of factor VIII and von Willebrand factor (VWF) lowered in individuals with blood group O compared to individuals groups with non-O blood. This research is aimed to investigate whether plasma volume are correlated with the levels of factor VIII in cryoprecipitation. In this study purposive sampling is done in which 25 bags of cryoprecipitate materials (was storage for 11 months) from all types of blood group which were taken from storage, thawed, weighed and the plasma volume measured. Factor VIII was measured by coagulometric method. The researcher used Spearman correlation test to analyze the product, with significance degree p<0.05 and confidence interval 95%. In this study it is found plasma volume which was not related to the factor VIII level in cryoprecipitattion substance (p=0.585). Mean plasma volume of the cryoprecipitated matter was 56 mL, mean factor VIII was 83.3UI. Highest factor VIII level was 160.6 UI of cryoprecipitated blood group AB and lowest factor VIII level was 21.3 UI of cryoprecipitated blood group A.

scholarly journals Clinical guidelines for cryoprecipitate transfusions

2020 ◽  
Vol 65 (1) ◽  
pp. 87-114
Author(s):  
G. M. Galstyan ◽  
T. V. Gaponova ◽  
E. B. Zhiburt ◽  
E. N. Balashova ◽  
A. L. Berkovskiy ◽  
...  
Keyword(s):  
Factor Viii ◽  
Von Willebrand Factor ◽  
Factor Xiii ◽  
Fresh Frozen Plasma ◽  
Von Willebrand Disease ◽  
Fresh Frozen ◽  
Congenital Afibrinogenemia ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Disease Factor

Background. Cryoprecipitate is made from fresh-frozen plasma (FFP) and contains fibrinogen, factor VIII, factor XIII, von Willebrand factor, fibronectin and fibrinogen.Aim. To provide information on the composition and methods of production, storage, transportation and clinical use of cryoprecipitate.General findings. Cyoprecipitate is manufactured by slowly thawing FFP at 1–6°C. This precipitates out cryoproteins: factor VIII, von Willebrand factor, factor XIII, fibronectin and fibrinogen. After centrifugation, the cryoproteins are resuspended in a reduced volume of plasma. Cryoprecipitate is stored at temperatures not exceeding –25° С for 36 months. Indications for cryoprecipitate transfusion are hemophilia A, von Willebrand disease, factor XIII deficiency, congenital afibrinogenemia and hypofibrinogenemia, acquired hypofibrinogenemia. These indications can occur in obstetrics, neonatology, cardiac surgery, neurosurgery, hematology, orthopaedics, and general surgery during liver transplantation and disseminated intravascular coagulation.

scholarly journals Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A

2020 ◽  
Vol 18 (5) ◽  
pp. 1081-1086
Author(s):  
Judit Rejtő ◽  
Oliver Königsbrügge ◽  
Ella Grilz ◽  
Stefanie Hofer ◽  
Lisa‐Marie Mauracher ◽  
...  
Keyword(s):  
Factor Viii ◽  
Blood Group ◽  
Von Willebrand Factor ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Von Willebrand ◽  
Willebrand Factor

The Relationship between ABO Groups, Factor VIII, von Willebrand Factor Levels and Platelet Function Analysis Using Cone and Plate(let) Analyzer.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4024-4024
Author(s):  
Maria Lourdes Barjas Castro ◽  
Aline Crucello ◽  
Heloise P. Fernandes ◽  
Norma C. Sousa ◽  
Joyce M. Annichino-Bizzacchi ◽  
...  
Keyword(s):  
Factor Viii ◽  
Blood Group ◽  
Platelet Function ◽  
Von Willebrand Factor ◽  
Function Analysis ◽  
World Health ◽  
Enzyme Linked Immunosorbent Assay ◽  
Abo Blood Group ◽  
Von Willebrand ◽  
Willebrand Factor

Abstract ABO blood group has been described to influence levels of von Willebrand factor (VWF), as well as factor VIII. Individuals carrying O allele have significant lower plasma levels of these factors. Indeed, recently non-O individuals have been described to have increased risk for both, arterial and venous thrombotic disease. VWF mediate platelet interaction with areas of damage blood vessel wall. Thus, it could be interesting to evaluate the possible influence of the ABO group in this interaction, particularly in situations in which low levels of VWF are close to those found in VW disease (such in O group). Cone and plate(let) analyzer (CPA) represent a simple and fast method, that allow the evaluation of platelet function (adhesion as well aggregation) in whole blood under shear conditions, closer to physiological conditions. In this method, no platelet agonists are needed and interaction with fibrinogen and VWF is particularly evaluated. The aim of the present study was to evaluate the influence of ABO group in platelet function using CPA. Samples from 15 male blood donors with no history of drug intake, were submitted to ABO serology and molecular analysis, VWF:Ag, FVIII dosages, and CPA analysis using Impact-R (Diamed - Switzerland), according to manufacturer’s instructions. ABO phenotypes were determined by agglutination test using monoclonal and polyclonal anti-A, B and AB antibodies (Asem-NPBI, São Paulo Brazil; DiaMed SA, Suisse; DiaMed Latino América, Brazil). H antigen was determined using anti-H lectin from Ulex europaeus (DiaMed Latino América, Brazil). ABO genotyping was performed by polymerase chain reaction (PCR) amplification of exons 6 and 7 of the ABO gene, followed by diagnostic restriction enzyme digestion. Factor VIII coagulant was measured by a one stage clothing method using a factor-VIII deficient substrate. VWF:Ag was measured by an enzyme linked immunosorbent assay (ELISA) using polyclonal antiserum (Dako, Denmark). Lyophilised commercial reference preparations of VWF:Ag, and FVIII, standardized against the World Health Organization standard, were used as the standards in this study. The age of the donors ranged from 27–65 years (median = 42 years). The donors were distributed according to ABO groups: 5 = OO; 5 = AB; 5 = AO. Median levels of factor VIII, according to blood group were: OO= 79% (70–142%); AO= 87% (80–140%); AB= 112% (98–200%). Median levels of VWF, according to blood group were: OO= 79% (50–99%); AO= 82% (73–120%); AB= 169% (92–250%). CPA analysis presented the following results: median AS in μm2 (average size) - OO= 24 (23–42); AO= 33 (24–42); AB= 23 (21–24) - median SC in % (surface coverage) - OO= 7.1 (4–13); AO= 8 (5–8); AB= 6.9 (4.8–8). No significant differences using Wilcoxon’s rank sum test were found among groups, when platelet function was analyzed. In conclusion, our results suggest that, although O allele carriers present lower levels of both factor VIII and VWF, the use of platelet function analysis does not seem to predict the risk for bleeding or thrombosis, according to individual ABO blood group.

scholarly journals Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor

Blood ◽  
1989 ◽  
Vol 73 (4) ◽  
pp. 990-993 ◽  
Author(s):  
KH Orstavik ◽  
L Kornstad ◽  
H Reisner ◽  
K Berg
Keyword(s):  
Plasma Concentration ◽  
Factor Viii ◽  
Blood Group ◽  
Von Willebrand Factor ◽  
Von Willebrand Disease ◽  
Type I ◽  
Genetically Determined ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Blood Group H

Abstract A significant fraction (30%) of the genetically determined variance in plasma concentration of the von Willebrand factor antigen (vWf:Ag) has been shown to be related to ABH determinants. Individuals with blood group O, who have the highest amounts of blood group H substance, have the lowest concentration of vWf:Ag. The Lewis substances, Le(a) and Le(b), are biochemically closely related to the ABH substances as both can be produced from the same precursor substance. We studied the effect of the presence of the Lewis antigens on the plasma concentration of vWf:Ag and factor VIII antigen (VIII:Ag) in 323 individuals of different ABO groups from a series of twins and in 58 blood donors of blood group O. Among persons belonging to blood group O, those with the Le(a) antigen had a higher concentration of both vWf:Ag and VIII:Ag than individuals lacking Le(a). Le(a+b-) people are nonsecretors and Le(a-b+) people are secretors of ABH substance. Thus, the lowest concentration of vWf:Ag and VIII:Ag was found in group O secretors. The effect is most likely due to an effect of the secretor locus. This finding may be of importance for the detection of carriers of hemophilia A and for the diagnosis of type I von Willebrand disease.

scholarly journals Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor

Blood ◽  
1989 ◽  
Vol 73 (4) ◽  
pp. 990-993
Author(s):  
KH Orstavik ◽  
L Kornstad ◽  
H Reisner ◽  
K Berg
Keyword(s):  
Plasma Concentration ◽  
Factor Viii ◽  
Blood Group ◽  
Von Willebrand Factor ◽  
Von Willebrand Disease ◽  
Type I ◽  
Genetically Determined ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Blood Group H

A significant fraction (30%) of the genetically determined variance in plasma concentration of the von Willebrand factor antigen (vWf:Ag) has been shown to be related to ABH determinants. Individuals with blood group O, who have the highest amounts of blood group H substance, have the lowest concentration of vWf:Ag. The Lewis substances, Le(a) and Le(b), are biochemically closely related to the ABH substances as both can be produced from the same precursor substance. We studied the effect of the presence of the Lewis antigens on the plasma concentration of vWf:Ag and factor VIII antigen (VIII:Ag) in 323 individuals of different ABO groups from a series of twins and in 58 blood donors of blood group O. Among persons belonging to blood group O, those with the Le(a) antigen had a higher concentration of both vWf:Ag and VIII:Ag than individuals lacking Le(a). Le(a+b-) people are nonsecretors and Le(a-b+) people are secretors of ABH substance. Thus, the lowest concentration of vWf:Ag and VIII:Ag was found in group O secretors. The effect is most likely due to an effect of the secretor locus. This finding may be of importance for the detection of carriers of hemophilia A and for the diagnosis of type I von Willebrand disease.

Familial Clustering of Factor VIII and von Willebrand Factor Levels

1998 ◽  
Vol 79 (02) ◽  
pp. 323-327 ◽  
Author(s):  
Jeanine Houwing-Duistermaat ◽  
Hans van Houwelingen ◽  
Jeroen Eikenboom ◽  
Rogier Bertina ◽  
Frits Rosendaal ◽  
...  
Keyword(s):  
Factor Viii ◽  
Blood Group ◽  
Von Willebrand Factor ◽  
Familial Aggregation ◽  
Univariate Analysis ◽  
Clotting Factor ◽  
Thrombotic Risk ◽  
Plasma Factor ◽  
Von Willebrand ◽  
Willebrand Factor

SummaryRecently, we found that high levels of clotting factor VIII (>150 IU/dl) are common and make an important contribution to thrombotic risk. The determinants of high factor VIII:C are unclear and might be partly genetic. Therefore, we tested the influence of age, blood group and von Willebrand factor (VWF) levels on factor VIII:C levels, and investigated whether factor VIII:C levels are genetically determined. We performed an analysis of 564 female relatives of hemophilia A patients, who had visited our center for genetic counseling. In univariate analysis, AB0 blood group, age and VWF antigen (VWF:Ag) levels all influenced factor VIII:C levels. After adjustment for the effect of VWF:Ag levels, both blood group and age still had an effect on factor VIII:C levels. In sister pairs, the Pearson correlation coefficient between factor VIII:C levels was 0.17 (p = 0.024) and this correlation remained positive (0.15, p = 0.046) after correction for the influence of VWF:Ag. In mother-daughter pairs, no correlation of factor VIII:C levels was found. The correlation of VWF:Ag levels in sisterpairs was 0.41 (p <0.001) and in mother-daughter pairs 0.44 (p <0.001), in line with the assumption that VWF:Ag levels are under control of autosomal genes. Familial influence on plasma factor VIII:C and VWF:Ag levels was investigated with a recently developed familial aggregation test. This test verifies whether familial aggregation of a particular parameter exists in a set of pedigrees. In 435 women from 168 families, factor VIII:C as well as VWF:Ag levels correlated significantly within families, which suggests a familial influence. The familial aggregation was more prominent for VWF:Ag levels than for factor VIII:C levels, possibly because the genetic effect on VWF:Ag levels is larger than on factor VIII:C levels. Our results support the presence of a familial influence on factor VIII:C as well as on VWF:Ag levels.Our results support the presence of a familial influence on factor VIII:C as well as on VWF:Ag levels.

Sign in / Sign up

Export Citation Format

Share Document